# Bortezomib as First Salvage Therapy for Myeloma Patients Previously Exposed to Bortezomib as Initial Treatment.

> **NCT02797041** · — · UNKNOWN · sponsor: **IRCCS Centro di Riferimento Oncologico della Basilicata** · enrollment: 100 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Bortezomib

## Key facts

- **NCT ID:** NCT02797041
- **Lead sponsor:** IRCCS Centro di Riferimento Oncologico della Basilicata
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-08
- **Primary completion:** 2016-03
- **Final completion:** 2016-06
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2016-06-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02797041

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02797041, "Bortezomib as First Salvage Therapy for Myeloma Patients Previously Exposed to Bortezomib as Initial Treatment.". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT02797041. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*